Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,150,995 papers from all fields of science
Search
Sign In
Create Free Account
Refractory Adult Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia that occurs in adulthood and does not respond to treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
13 relations
Atypical lymphocyte
Bone Marrow
Hematopoietic and Lymphoid Cell
Hematopoietic and Lymphoid Tissue
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience
M. Ansuinelli
,
A. Vitale
,
+15 authors
R. Foà
Blood
2019
Corpus ID: 209250181
Background. Hematologic and, to a lesser extent, molecular relapsed/refractory in adult acute lymphoblastic leukemia (R/R ALL) is…
Expand
2018
2018
[The investigation of CAG regimen in relapsed and refractory adult acute lymphoblastic leukemia].
Y. Wang
,
Y. Chen
,
+5 authors
S. Zhang
Zhonghua xue ye xue za zhi = Zhonghua xueyexue…
2018
Corpus ID: 29161924
2012
2012
Clofarabine‐based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience
P. Barba
,
A. Sampol
,
+7 authors
J. Ribera
American journal of hematology/oncology
2012
Corpus ID: 5100454
The present study reports the Spanish PETHEMA group experience in 31 heavily pretreated relapsed/refractory acute lymphoblastic…
Expand
2011
2011
Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience
P. Barba
,
A. Sampol
,
+14 authors
J. Ribera
2011
Corpus ID: 208326634
Abstract 4246 Background: Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have a very poor outcome with…
Expand
2009
2009
A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia.
M. Hafeez
,
A. Shaharyar
,
N. Zia
,
H. Rasheed
Journal of Clinical Oncology
2009
Corpus ID: 20666854
e18002 Background: Most patients with adult ALL eventually relapse. Salvage regimens in these patients and in patients with…
Expand
2006
2006
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)
S. Giebel
,
M. Krawczyk-Kuliś
,
+8 authors
on behalf of the Israeli Cll Study Group
Annals of Hematology
2006
Corpus ID: 22002409
Outcome of adults with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) or who relapse soon after…
Expand
2000
2000
A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
P. Rosen
,
C. Rankin
,
+6 authors
F. Appelbaum
Leukemia research : a Forum for Studies on…
2000
Corpus ID: 13064299
1998
1998
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia
M. Weiss
,
P. Drullinsky
,
P. Maslak
,
D. Scheinberg
,
D. Golde
Leukemia
1998
Corpus ID: 25720860
Relapsed or refractory adult acute lymphoblastic leukemia (ALL) carries a grave prognosis. The most promising strategy for curing…
Expand
1986
1986
Therapy of Refractory Adult Acute Lymphoblastic Leukemia with Vincristine and Prednisone plus Tandem Methotrexate and L‐Asparaginase Results of a Cancer and Leukemia Group B Study
H. Terebelo
,
K. Anderson
,
+4 authors
J. Berenberg
American Journal of Clinical Oncology
1986
Corpus ID: 41153132
Methotrexate (MTX) and L-asparaginase (ASP) are effective agents in the treatment of acute lymphoblastic leukemia (ALL). The…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE